Business, energy, technology, markets and global industry news from Business News Today

immuno-oncology

PharmaDeviceNews immuno-oncology
Representative image: Clinical analytics and gastrointestinal imaging scene reflecting Seres Therapeutics’ SER-155 data in checkpoint inhibitor-related enterocolitis and the emerging role of microbiome therapeutics in cancer supportive care.
Pharma & Biotech

Why SER-155 could become a key clinical catalyst for Seres Therapeutics

Seres Therapeutics Inc. (Nasdaq: MCRB) has reported early clinical data for SER-155 in immune checkpoint inhibitor-related enterocolitis, a gastrointestinal immune-related adverse event that can interrupt cancer immunotherapy. The investigator-sponsored study evaluated the live biotherapeutic in 15 patients with moderate to severe disease and showed an immunosuppressive free clinical response in 80 percent of participants at

Read More
Representative image: Clinician reviewing lung CT scans, reflecting MAIA Biotechnology’s ateganosine data in third-line non-small cell lung cancer and the evolving search for new NSCLC treatment strategies.
Pharma & Biotech

MAIA Biotechnology reports stronger ateganosine data in third-line non-small cell lung cancer

MAIA Biotechnology has reported positive initial efficacy data from Part C of the Phase 2 THIO-101 expansion trial evaluating ateganosine followed by cemiplimab in third-line advanced non-small cell lung cancer. The clinical-stage oncology drug developer said the regimen produced a 90.5 percent interim disease control rate among efficacy-evaluable patients, placing its telomere-targeting strategy back in

Read More
Pharma & Biotech

Agenus BOTBAL survival data challenges expectations in MSS metastatic colorectal cancer

Explore how Agenus BOTBAL achieved 33% three-year survival in refractory MSS colorectal cancer and what Phase 3 must prove next.

Read More
Representative image: Biopharmaceutical manufacturing facility illustrating Orion Corporation and Shilpa Medicare’s partnership to develop and supply a nivolumab biosimilar for the European oncology market.
Pharma & Biotech

Shilpa Medicare secures Orion for European nivolumab biosimilar commercialization and supply

Discover how Orion and Shilpa Medicare’s nivolumab biosimilar deal could reshape European oncology access, pricing and hospital procurement.

Read More
Representative image: A clinical researcher reviews head and neck cancer scans and blood samples as Natera and Aveta Biomics integrate Signatera ctDNA monitoring into the global Phase 3 trial of APG-157.
Pharma & Biotech

Natera and Aveta Biomics bring Signatera into APG-157 Phase 3 head and neck cancer trial

See how Natera’s Signatera could sharpen APG-157’s Phase 3 evidence in head and neck cancer and what risks remain. Read the analysis.

Read More
Representative image: Oncology specialists review colorectal cancer scans and survival data as Agenus prepares to present three-year BOT+BAL findings in MSS metastatic colorectal cancer at ESMO GI 2026.
Pharma & Biotech

Agenus prepares ESMO GI 2026 survival update as BOT+BAL enters its Phase 3 test

Read how Agenus’ three-year BOT+BAL survival update could reshape expectations in refractory MSS metastatic colorectal cancer.

Read More
Representative image: Voro Therapeutics and Alloy Therapeutics are advancing masked T-cell engager research aimed at improving tumor-selective cancer immunotherapy.
Pharma & Biotech

Voro and Alloy target safer masked T-cell engager therapies in oncology

Find out how Voro Therapeutics and Alloy Therapeutics aim to advance safer masked T-cell engager cancer therapies.

Read More
Representative image: Cancer research team reviews tumor data as Harbour BioMed’s HBM7004 advances toward clinical testing for advanced solid tumors.
Pharma & Biotech

Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets

Find out how Harbour BioMed’s HBM7004 China IND acceptance could reshape B7-H4 solid tumor immunotherapy development.

Read More
Representative image of a modern pathology laboratory where automated PD-L1 cancer diagnostic testing is supporting faster immuno-oncology treatment decisions, reflecting Agilent Technologies’ expanded FDA approval for PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform.
Medical Devices & Diagnostics

Agilent wins FDA backing to move more Keytruda-linked PD-L1 testing onto Dako Omnis

Find out how Agilent’s expanded PD-L1 test approval could change automated cancer diagnostics and oncology lab workflows.

Read More
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026

See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.

Read More